- Biotechnology company developing precision genetic medicines – Beam Therapeutics (NASDAQ:BEAM) said that its CFO, Terry-Ann Burrell, will be leaving the company effective August 9, 2024.
- She will be pursuing a new opportunity as vice chairman of investment banking at JPMorgan Chase.
- As part of a transition process, the company has initiated a search for a successor.
- “Terry-Ann has been an invaluable member of our team over the last five years, and her leadership was instrumental in the success of our IPO, the build-out of our finance and corporate affairs functions, and the development of Beam’s organization and culture,” said John Evans, CEO.
- The stock was trading 0.56% lower on Monday during pre-market hours of trade.
2024-07-15